Have a feature idea you'd love to see implemented?
Let us know!
VRNA Verona Pharma plc
Price (delayed)
$34.45
Market cap
$2.8B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.6
Enterprise value
$2.61B
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved,
Highlights
The EPS has dropped by 150% year-on-year and by 100% since the previous quarter
VRNA's net income has shrunk by 143% YoY and by 98% QoQ
Key stats
What are the main financial stats of VRNA
Market
Valuations
Earnings
Shares outstanding
81.24M
Market cap
$2.8B
Enterprise value
$2.61B
Price to earnings (P/E)
N/A
Price to book (P/B)
16.6
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$119.32M
EBITDA
-$118.43M
Free cash flow
-$53.89M
Per share
Balance sheet
Liquidity
EPS
-$1.6
Free cash flow per share
-$0.67
Book value per share
$2.08
Revenue per share
$0
TBVPS
$5.35
Total assets
$434.12M
Total liabilities
$265.85M
Debt
$218.53M
Equity
$168.27M
Working capital
$367.95M
Debt to equity
1.3
Current ratio
8.61
Quick ratio
8.37
Net debt/EBITDA
1.57
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-37.9%
Return on equity
-55.4%
Return on invested capital
-121%
Return on capital employed
-30.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VRNA stock price
How has the Verona Pharma stock price performed over time
Intraday
2.32%
1 week
-1.37%
1 month
19.74%
1 year
157.09%
YTD
73.29%
QTD
19.74%
Financial performance
How have Verona Pharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$131.03M
Net income
-$125.45M
Gross margin
N/A
Net margin
N/A
VRNA's net income has shrunk by 143% YoY and by 98% QoQ
The operating income has plunged by 110% YoY and by 81% from the previous quarter
Verona Pharma's revenue has plunged by 100% YoY
The company's gross profit has shrunk by 100% YoY
Growth
What is Verona Pharma's growth rate over time
Valuation
What is Verona Pharma stock price valuation
P/E
N/A
P/B
16.6
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has dropped by 150% year-on-year and by 100% since the previous quarter
VRNA's P/B is 170% above its last 4 quarters average of 6.0
VRNA's equity is down by 38% year-on-year and by 25% since the previous quarter
Verona Pharma's revenue has plunged by 100% YoY
Efficiency
How efficient is Verona Pharma business performance
Verona Pharma's ROE has plunged by 173% YoY and by 121% from the previous quarter
Verona Pharma's ROA has plunged by 113% YoY and by 79% from the previous quarter
The ROIC has grown by 35% YoY but it has contracted by 22% from the previous quarter
Dividends
What is VRNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VRNA.
Financial health
How did Verona Pharma financials performed over time
Verona Pharma's total assets is 63% more than its total liabilities
Verona Pharma's current ratio has plunged by 67% YoY and by 53% from the previous quarter
Verona Pharma's quick ratio has shrunk by 66% YoY and by 51% QoQ
The debt is 30% greater than the equity
VRNA's equity is down by 38% year-on-year and by 25% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.